Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2024 09:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 06, 2024 16:15 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
February 20, 2024 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
January 31, 2024 16:05 ET | Source: TransCode Therapeutics, Inc.

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
January 29, 2024 08:30 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 22, 2024 16:45 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics closes public offering
January 18, 2024 13:27 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 12, 2024 16:05 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO
January 11, 2024 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Announces Reverse Stock Split
January 04, 2024 08:05 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

An Open Letter to Shareholders of TransCode Therapeutics, Inc.

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right